Skip to Content
Merck
CN

H-004

Hydromorphone solution

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H19NO3
CAS Number:
Molecular Weight:
285.34
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

certified reference material

Quality Level

form

liquid

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal), kontrollierte Droge in Deutschland

concentration

1 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CN1CC[C@@]23[C@H]4CCC(=O)[C@@H]2Oc5c(O)ccc(C[C@@H]14)c35

InChI

1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

InChI key

WVLOADHCBXTIJK-YNHQPCIGSA-N

Gene Information

human ... OPRM1(4988)

General description

A certified reference standard suitable for use as a starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis, clinical toxicology, and pain prescription monitoring to urine drug testing and pharmaceutical research. Hydromorphone, marketed under brand names including Palladone and Dilaudid®, is a very potent opioid analgesic. The drug is often used medicinally as an alternative to morphine for treatment of pain or as a cough suppressant for painful coughing resulting from continued bronchial irritation.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Dilaudid is a registered trademark of Purdue Pharma L.P.

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.


Still not finding the right product?

Explore all of our products under Hydromorphone solution


signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

监管及禁止进口产品

This item has



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Protocols

为了使用β-葡糖醛酸酶优化水解,必须对每种待分析的葡糖苷酸代谢物进行某些因素的评估,例如孵育时间、温度、水解pH、酶源和酶浓度。

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Articles

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.


Kyung Hee Lee et al.
Journal of opioid management, 8(4), 243-252 (2012-09-04)
To evaluate the effectiveness of OROS® hydromorphone in reducing breakthrough pain (BTP) medication frequency in Korean patients with chronic cancer pain. Multicenter, prospective, open-label, phase IV study. Patients with chronic malignant pain using immediate-release oxycodone more than two times per
Bonnie L Hay Kraus
Veterinary anaesthesia and analgesia, 40(1), 28-34 (2012-10-23)
The goal of this study was to evaluate the effectiveness of maropitant (Cerenia(®)) in preventing vomiting after premedication with hydromorphone. Randomized, blinded, prospective clinical study. Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed
Martin E Hale et al.
Journal of opioid management, 8(5), 299-314 (2012-12-19)
This analysis was designed to assess the pooled safety and tolerability of once-daily hydromorphone extended release (ER) (OROS® hydromorphone ER) in opioid-naïve and opioid-tolerant patients with chronic cancer or noncancer pain. Safety results were pooled from 13 controlled and uncontrolled



Global Trade Item Number

SKUGTIN
H-004-1ML04061833660300